Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:1032-1038

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhu, X.-F.
Right arrow Articles by Schonfeld, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhu, X.-F.
Right arrow Articles by Schonfeld, G.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:1032-1038.)
© 1997 American Heart Association, Inc.


Articles

Organ Loci of Catabolism of Short Truncations of ApoB

Xian-Feng Zhu; Davide Noto; Rick Seip; Aviv Shaish; ; Gustav Schonfeld

From the Division of Atherosclerosis, Nutrition, and Lipid Research, Washington University School of Medicine, St Louis, Mo (X.F.Z., A.S., G.S.); Cattedra Di Patologia Speciale Medica, E Matodiolgia Clinica, Istituto di Patologia Medica II, Universita di Palermo, Italy (D.N.); and the Human Performance Lab, University of Nebraska, Kearney (R.S.).

Correspondence to Xien-Feng Zhu, Division of Atherosclerosis, Nutrition, and Lipid Research, Washington University School of Medicine, 660 S. Euclid Ave, St. Louis, MO 63110.

Abstract Truncations of apolipoprotein (apo) B shorter than 3200 amino acids (3200/4536=apoB-70) do not possess the LDL receptor–recognition domain and are not recognized by altered cells with normally functioning LDL receptors. To ascertain which organs remove such truncated apoB–containing particles, we isolated apoB-31–, apoB-38.9–, and apoB-43.7–containing particles from plasmas of familial hypobetalipoproteinemia heterozygous humans by a combination of sequential ultracentrifugation and preparative electrophoresis. Particles with labeled 125I- or 131I-dilactitol tyramine (I-DLT), were injected into New Zealand White rabbits, along with I-DLT–apoB-100–containing LDLs, and the decay of 125I- and 131I-TCA–precipitated counts was followed over 24 hours. At the end of 24 hours, rabbits were anesthetized and their bodies perfused. Organs were removed and homogenized, and TCA-precipitable counts determined. Fractional catabolic rates of apoB truncation particles were two to five times greater than those of apoB-100 LDLs. ApoB truncations accumulated in adrenals at one fifth the rates of apoB-100 LDL, compatible with the functional absences of LDL receptor–recognition domains in truncated apoBs. The major organ of uptake for apoB-100-LDLs was the liver, whereas truncation particles were readily removed by the kidney (kidney: liver uptake ratios were 0.10 to 0.30 for apoB-100 LDLs and 1.03 to 3.77 for truncations). Spleens accumulated little of either apoB-100 or truncation particles, suggesting particles were not "damaged" or aggregated. Thus, the absence of >56% of the carboxyl end of apoB-100 increases the plasma clearance and redirects the organ uptake of the apoB truncation–containing lipoproteins from liver to kidney.


Key Words: lipoproteins • apoB • apoB truncations • dilactitol tyramine




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. R. Sankatsing, S. W. Fouchier, S. de Haan, B. A. Hutten, E. de Groot, J. J.P. Kastelein, and E. S.G. Stroes
Hepatic and Cardiovascular Consequences of Familial Hypobetalipoproteinemia
Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1979 - 1984.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
Z. Chen, R. L. Fitzgerald, G. Li, N. O. Davidson, and G. Schonfeld
Hepatic secretion of apoB-100 is impaired in hypobetalipoproteinemic mice with an apoB-38.9-specifying allele
J. Lipid Res., January 1, 2004; 45(1): 155 - 163.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
G. Schonfeld
Familial hypobetalipoproteinemia: a review
J. Lipid Res., May 1, 2003; 44(5): 878 - 883.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
Z. Chen, R. L. Fitzgerald, J. E. Saffitz, C. F. Semenkovich, and G. Schonfeld
Amino Terminal 38.9% of Apolipoprotein B-100 Is Sufficient to Support Cholesterol-Rich Lipoprotein Production and Atherosclerosis
Arterioscler. Thromb. Vasc. Biol., April 1, 2003; 23(4): 668 - 674.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Z. Chen, R. L Fitzgerald, and G. Schonfeld
Hypobetalipoproteinemic Mice with a Targeted Apolipoprotein (Apo) B-27.6-specifying Mutation. IN VIVO EVIDENCE FOR AN IMPORTANT ROLE OF AMINO ACIDS 1254-1744 OF ApoB IN LIPID TRANSPORT AND METABOLISM OF THE ApoB-CONTAINING LIPOPROTEIN
J. Biol. Chem., April 12, 2002; 277(16): 14135 - 14145.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
J. Wu, J. Kim, Q. Li, P.-Y. Kwok, T. G. Cole, B. Cefalu, M. Averna, and G. Schonfeld
Known mutations of apoB account for only a small minority of hypobetalipoproteinemia
J. Lipid Res., May 1, 1999; 40(5): 955 - 959.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
Z. Chen, R. L. Fitzgerald, M. R. Averna, and G. Schonfeld
A Targeted Apolipoprotein B-38.9-producing Mutation Causes Fatty Livers in Mice Due to the Reduced Ability of Apolipoprotein B-38.9 to Transport Triglycerides
J. Biol. Chem., October 13, 2000; 275(42): 32807 - 32815.
[Abstract] [Full Text] [PDF]